人胚胎干细胞在药源性心脏和肝毒性研究中的应用进展  

Application of human embryonic stem cells in study of drug-induced cardiotoxicity and hepatotoxicity

作　　者：王淑颜 汪溪洁[1] 胡晓敏[2] 马璟[1] 

机构地区：[1]中国医药工业研究总院上海医药工业研究院国家上海新药安全评价研究中心,上海201203 [2]国家食品药品监督管理局药品审评中心,北京100038

出　　处：《中国药理学与毒理学杂志》2014年第4期612-617,共6页Chinese Journal of Pharmacology and Toxicology

基　　金：国家科技重大专项(2012ZX09302002);上海市科委项目(13140900900)~~

摘　　要：人胚胎干细胞(hESC)具有无限增殖和诱导分化为心肌细胞和肝细胞的能力,可应用于新药筛选和药物的安全性评价过程。心脏毒性和肝毒性是新药研发失败、被监管以及撤市的主要原因。hESC分化的心肌细胞和肝细胞具有结构和功能特性,能在体外模拟药物的心脏和肝毒性,且基于hESC诱导分化的心肌细胞和肝细胞建立的体外新药安全评价系统,具有实验周期短、用药量少、成本低和有效避免种属差异等优点。因此,hESC分化的心肌和肝细胞在药物毒理学研究中具有广阔的应用前景。Human embryonic stem cells （hESC）, characterized by unique capacities of self-renewal and differentiation into cardiomyocytes and hepatocytes, can be used in new drug screening and drug safety evaluation processes. Cardiotoxicity and hepatotoxicity are major obstacles to development and marketing of new drugs, hESC-derived cardiomyocytes and hepatocytes have structural and functional characteristics, which can be used for cardiotoxicity and hepatotoxicity testing in vitro and for building a drug safety evaluation system in vitro that has the advantage of short experiment cycles, small dose, low cost and few species differences, hESC-derived cardiomyocytes and hepatocytes have broad prospects of application in toxicology.

关 键 词：人胚胎干细胞 心脏毒性 肝毒性 安全性评价 

分 类 号：R994.3[医药卫生—毒理学]